Literature DB >> 23471975

Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis.

Wei-Yih Chiu1, Jang-Jaer Lee, Keh-Sung Tsai.   

Abstract

CONTEXT: Bisphosphonates effectively increase bone mineral density and reduce fracture risk in patients with osteoporosis, but there are concerns about osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFFs) in the long-term users. So far both complications have not been reported as occurring simultaneously in an osteoporotic individual on oral alendronate.
OBJECTIVE: The aim of this study was to report a postmenopausal woman presenting with concomitant ONJ and AFF on oral alendronate treatment. SUBJECT, MEASURES, AND RESULT: The patient was a 63-year-old woman with a history of rheumatoid arthritis for 30 years and diabetes for 3 years. Spinal compression fractures at levels L3 and L4 were documented, and she took alendronate 70 mg weekly for 7 years. She is the first case whose dental periapical imaging and pelvic radiography documented her ONJ and AFF, which developed subsequently within 6 months.
CONCLUSIONS: This case report supports the association of both ONJ and AFF with long-term oral bisphosphonate therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23471975     DOI: 10.1210/jc.2012-4144

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties.

Authors:  N Hassler; S Gamsjaeger; B Hofstetter; W Brozek; K Klaushofer; E P Paschalis
Journal:  Osteoporos Int       Date:  2014-10-15       Impact factor: 4.507

2.  Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.

Authors:  A Sánchez; R Blanco
Journal:  Osteoporos Int       Date:  2016-11-20       Impact factor: 4.507

3.  Summary of the various treatments for osteonecrosis of the femoral head by mechanism: A review.

Authors:  Cheng Wang; Jiang Peng; Shibi Lu
Journal:  Exp Ther Med       Date:  2014-06-26       Impact factor: 2.447

4.  Oral Bisphosphonate Induced Recurrent Osteonecrosis of Jaw with Atypical Femoral Fracture and Subsequent Mandible Fracture in the Same Patient: A Case Report.

Authors:  Ameet Pispati; Varun Pandey; Roopak Patel
Journal:  J Orthop Case Rep       Date:  2018 May-Jun

5.  Osteonecrosis of the Jaw and Bilateral Atypical Femoral Fracture Both Occurring During Treatment for Osteoporosis: A Case Report.

Authors:  Edelissa Payumo; Beinjerinck Ivan Cudal; Thelma Crisostomo
Journal:  J ASEAN Fed Endocr Soc       Date:  2018-09-12

6.  Prevalence and Risk Factors of Atypical Femoral Fracture Bone Scintigraphic Feature in Patients Experiencing Bisphosphonate-Related Osteonecrosis of the Jaw.

Authors:  Chang-Hee Lee; Seung Hyun Son; Chae Moon Hong; Ju Hye Jeong; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Tae-Geon Kwon; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2018-07-16

Review 7.  The role of antiresorptive drugs and medication-related osteonecrosis of the jaw in nononcologic immunosuppressed patients: A systematic review.

Authors:  Roberto Sacco; Julian Woolley; Julian Yates; Monica Diuana Calasans-Maia; Oladapo Akintola; Vinod Patel
Journal:  J Res Med Sci       Date:  2021-03-31       Impact factor: 1.852

Review 8.  Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation.

Authors:  Kazuhiro Imai
Journal:  Clin Interv Aging       Date:  2013-06-07       Impact factor: 4.458

9.  Do Bisphosphonate-related Atypical Femoral Fractures and Osteonecrosis of the Jaw Affect the Same Group of Patients? A Pilot Study.

Authors:  Haitham Afif; Sebastian Mukka; Göran Sjödén; Arkan S Sayed-Noor
Journal:  Orthop Rev (Pavia)       Date:  2014-01-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.